The Principal Investigator and Deputy Director for Research at NOVA Medical School, João Conde, was recently awarded an honorable mention by Basinnov Life Sciences (FHC Group) as part of the Basinnov Innovation Award 2024. The presentation of the award took place during the HealthTech Connect satellite event of the Web Summit, held at 8Marvila in Lisbon on November 13.
The Basinnov Innovation Award 2024 aimed to recognize and reward research projects in oncology and immunotherapy treatments based on the quality and relevance of the results, as well as the maturity of the idea's development. The project "NeuroNasal OncoGel for Pediatric Brain Cancer" from the Cancer Nanomedicine research group at NOVA Medical School, led by João Conde, stood out for what the researcher described as its “originality and impact in the fields of nanomedicine and oncology innovation.” Furthermore, he noted that “receiving this honorable mention positions the group in both the national and international scientific arena and represents an important milestone in my career as a researcher.”
The HealthTech Connect event was organized by EIT Health InnoStars Portugal and served as a meeting point for innovators, entrepreneurs, healthcare professionals, and other stakeholders to explore the latest advancements and challenges in health and technology.
NOVA Medical School was also represented at the event, at the Universidade Nova de Lisboa booth, with members from its research support services teams. It was a unique opportunity to present the School’s research vision and its process in developing innovative health solutions across all stages: discovery, preclinical development, clinical studies, and validation.
Basinnov Life Sciences, the entity behind the award, is part of the FHC Group – The Future of Healthcare, and is dedicated to the mission of identifying and supporting disruptive therapeutic solutions in oncology and immunotherapy.